Jean-Luc Coll , Grenoble University
-
Le 17 May 2024Amphi DEfalse false
-
11h30
Optically active nanosystems for photo-, radio-, or neutron-based theranostic treatments of cancer
Optically active nanosystems for photo-, radio-, or neutron-based theranostic treatments of cancer
Jean-Luc Coll, PhD
Team Cancer Targets and Experimental Therapeutics,
Univ. Grenoble Alpes, Inserm U1209, CNRS UMR5309, Institute for Advanced Biosciences
Abstract
I will present our recent work on the production of theranostic nanoparticles (TN) that we designed to combine diagnostic and therapeutic capabilities for the treatment of cancer. We are using a variety of materials, including metals, polymers and lipids, and we formulate them with different types of drugs and/or photoactive compounds.
They can then be used and tested in animal models as contrast agents to precisely detect and delineate the region to treat using MRI, X-rays, Near-infrared light or ultrasounds and, in addition, our NT can be remotely and precisely activated on site using non-ionizing and/or ionizing radiations to specifically deliver combined synergistic therapeutic activities to the target tumor cells and their microenvironment, allowing for more effective treatments with fewer side effects.
These nanosystems can also be used intraoperatively for optical guided surgery of cancer.
Biography
Jean-Luc Coll is Director of Research at INSERM and Team leader in the Institute for Advanced Biosciences in Grenoble.Dr Coll is a biologist with strong experience in oncology. He is using fluorescence, nanotechnologies, chemistry and large instruments for physics, to develop theranostic nanoparticles for the treatment of tumors and their metastases.
His Team is in particular focused on the use of near-infrared labeled nanoparticles to target tumors, guide surgery and enhance radiotherapy, phototherapy or innovative therapies. In addition to the developments of nanovectors, he is also involved in the generation of adapted medical devices.
